

# Calogero Camma

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6809204/calogero-camma-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19  
papers

649  
citations

13  
h-index

19  
g-index

19  
ext. papers

779  
ext. citations

7.1  
avg, IF

3.09  
L-index

#	Paper	IF	Citations
19	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 688-695	6.1	104
18	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 617-627	6.1	94
17	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2012</b> , 56, 850-60	11.2	91
16	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2013</b> , 57, 1046-54	11.2	78
15	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2014</b> , 59, 1692-705	11.2	64
14	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 1157-1166	7.9	53
13	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 658-66	13.4	34
12	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 324-30	3.3	30
11	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , <b>2017</b> , 37, 1389-1396	7.9	26
10	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	21
9	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , <b>2018</b> , 38, 715-723	7.9	15
8	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 936-42	3.3	14
7	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , <b>2018</b> , 38, 2108-2116	7.9	13
6	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. <i>Liver International</i> , <b>2021</b> , 41, 1105-1116	7.9	3
5	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2712-2719	7.9	3
4	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
3	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> ,	0.8	2

2	Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 862-863	6.1	1
1	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , <b>2021</b> , 41, 2179-2188	7.9	1